Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Equal Weight Rating by Wells Fargo & Company

Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from an overweight rating to an equal weight rating in a research note released on Friday morning, MarketBeat Ratings reports. The brokerage currently has $580.00 target price on the biopharmaceutical company's stock, down from their previous target price of $700.00.

A number of other research firms also recently weighed in on REGN. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. TD Cowen cut their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. Finally, Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $874.56.

Regeneron Pharmaceuticals Stock Down 18.5%

NASDAQ:REGN traded down $112.15 during trading hours on Friday, reaching $493.24. 6,307,887 shares of the stock were exchanged, compared to its average volume of 829,463. The stock has a market cap of $53.25 billion, a PE ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals has a twelve month low of $485.00 and a twelve month high of $1,211.20. The firm has a 50 day moving average of $584.25 and a 200 day moving average of $666.47.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the company posted $9.55 EPS. The company's quarterly revenue was down 3.7% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.71%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of REGN. Strs Ohio bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $21,805,000. Jacobi Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 8.1% in the 1st quarter. Jacobi Capital Management LLC now owns 1,425 shares of the biopharmaceutical company's stock worth $904,000 after acquiring an additional 107 shares during the last quarter. Acadian Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 69.0% in the 1st quarter. Acadian Asset Management LLC now owns 139,157 shares of the biopharmaceutical company's stock worth $88,233,000 after acquiring an additional 56,816 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in Regeneron Pharmaceuticals by 9.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 757 shares of the biopharmaceutical company's stock worth $480,000 after acquiring an additional 67 shares during the last quarter. Finally, Integrity Alliance LLC. bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $579,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.